Transgenic carrot plant-made edible vaccines against human infectious diseases
DOI:
https://doi.org/10.56511/JIPBS.2018.v5.i02.pp43-48Abstract
Infectious diseases are becoming a severe public health problem in every part of the world. In response to this, transgenic plants have turned into a new noticeable platform for the production of edible biopharmaceutical proteins, which will be evaluated for their efficiency as edible vaccines to protect against various infectious diseases in humans. Carrot is one plant species that has been used for producing biopharmaceutical proteins. Adjuvants to improve the immune response and bioencapsulation to provide a system for delivering antigens in a way that protects them from the low pH and enzyme digestion inside the gastrointestinal tract have also been developed. The use of transgenic carrot to express the target antigens has been a promising for the production of edible vaccines, because it consists of immunodominant epitopes. The edible vaccines developed so far using carrot could have a crucial role in protecting against various infectious diseases along with the potential to induce both systemic and mucosal immune responses in a mouse model. Herein, we summarize the progress of carrot-based expression systems that have been evaluated for edible vaccine development in the last five years
Keywords:
Carrot, adjuvant, antigen, edible vaccine, systemic and mucosal immune responsesDownloads
References
Brachman PS: Infectious diseases — past, present, and future. International Journal of Epidemiology 2003; 32:684-686.
Kong Q, Richter L, Yang YF: Arntzen CJ, Mason HS and Thanavala Y: Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proceedings of the National Academy of Sciences 2001; 20:11539.
Marquet-Blouin E, Bouche FB, Steinmetz A and Muller CP: Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin. Plant molecular biology 2003; 51:459-469.
Aliahmadi A,Rahmani N and Abdollahi M: Plant-derived human vaccines; an overview. International Journal of Pharmacology 2006; 2: 268-279.
Rosales-Mendoza S, Soria-Guerra RE, Lopez-Revilla R, Moreno-Fierros L and Alpuche-Solis AG: Ingestion of transgenic carrots expressing the Escherichia coli heat-labile enterotoxin B subunit protects mice against cholera toxin challenge. Plant Cell Reports 2008; 27:79-84.
Daniell H, Singh ND, Mason H and Streatfield SJ: Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Science 2009; 14: 669679.
Ulmer JB, Valley U, and Rappuoli R: Vaccine manufacturing: challenges and solutions. Nature Biotechnology 2006; 24:1377-1383.
Saejung W, Fujiyama K, Takasaki T, Ito M, Hori K, Malasit P, Watanabe Y, Kurane I and Seki T: Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 2007; 25: 6646-6654.
Rosales-Mendoza S and Tello-Olea MA: Carrot Cells: A Pioneering Platform for Biopharmaceuticals Production. Molecular Biotechnology 2015; 57:219-232.
Thomas S and Luxon BA: Vaccines based on structure-based design provide protection against infectious diseases. Expert Review of Vaccines 2013; 12:1301-1311.
Arakawa T, Yu J and Langridge WH: Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Advances in experimental medicine and biology 1999; 464:161-178.
Rigano MM, Alvarez ML, Pinkhasov J, Jin Y, Sala F, Arntzen CJ and Walmsley AM: Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Reports 2004; 22:502-508.
Rojas-Anaya E, Loza-Rubio E, Olivera-Flores MT and Gomez-Lim M: Expression of rabies virus G protein in carrots (Daucus carota). Transgenic Research 2009; 18:911-919.
Permyakova NV, Zagorskaya AA, Belavin PA, Uvarova EA, Nosareva OV, Nesterov AE, Novikovskaya AA, Zav'yalov EL, Moshkin MP and Deineko EV: Transgenic carrot expressing fusion protein comprising M. tuberculosis antigens induces immune response in mice. BioMed Research International 2015; 2015:417565.
Rosales-Mendoza S and Salazar-Gonzalez JA: Immunological aspects of using plant cells as delivery vehicles for oral vaccines. Expert Review of Vaccines 2014; 13:737-749.
Lindh I, Brave A, Hallengard D, Hadad R, Kalbina I, Strid A and Andersson S: Oral delivery of plantderived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses. Vaccine 2014; 32:2288-2293.
Kalbina I, Wallin A, Lindh I, Engstrom P, Andersson S and Strid K: A novel chimeric MOMP antigen expressed in Escherichia coli, Arabidopsis thaliana, and Daucus carota as a potential Chlamydia trachomatis vaccine candidate. Protein Expression and Purification 2011; 80:194-202.
Esmael H and Hirpa E: Review on Edible Vaccine. Academic Journal of Nutrition 2015; 1:40.
Su J, Zhu L, Sherman A, Wang X, Lin S, Kamesh A, Norikane JH, Streatfield SJ, Herzog RW and Daniell H: Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials 2015; 70:84-93.
Takeyama N, Kiyono H and Yuki Y: Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Therapeutic Advances in Vaccines 2015; 3:139 ‒ 154.
Lal P, Ramachandran VG, Goyal R and Sharma R: Edible vaccines: Current status and future. Indian journal of medical microbiology 2007; 25:93 ‒ 102.
Concha C, Canas R, Macuer J, Torres MJ, Herrada AA, Jamett F and Ibanez C:Disease prevention: An opportunity to expand edible plantbased vaccines? Vaccines 2017; 5.
Walsh G: Biopharmaceutical benchmarks 2014. Nature biotechnology 2014; 32:992-1000.
Tekoah Y, Shulman A, Kizhner T, Ruderfer I, Fux L, Nataf Y, Bartfeld D, Ariel T, Gingis-Velitski S, Hanania U and Shaaltiel Y: Large-scale production of pharmaceutical proteins in plant cell culturethe protalix experience. Plant biotechnology journal 2015; 13:1199-1208.
Rosales-Mendoza S, Salazar-González JA, Decker EL and Reski R: Implications of plant glycans in the development of innovative vaccines. Expert review of vaccines 2016; 15:915-925.
Baranski R: Genetic Transformation of Carrot (Daucus carota) and Other Apiaceae species. Transgenic Plant Journal©2008 Global Science Books; 2008.
Hardegger M and Sturm A: Transformation and regeneration of carrot (Daucus carota L.). Molecular Breeding 1998; 4:119-127.
Ekam VS, Udosen EO and Chigbu AE: Comparative effect of carotenoid complex from Golden Neo-Life Dynamite (GNLD) and carrot extracted carotenoids on immune parameters in albino Wistar rats. Nigerian journal of physiological sciences: official publication of the Physiological Society of Nigeria 2006; 21:1-4.
Lindh I, Wallin A, Kalbina I, Savenstrand H, Engstrom P, Andersson S and Strid A: Production of the p24 capsid protein from HIV-1 subtype C in Arabidopsis thaliana and Daucus carota using an endoplasmic reticulum-directing SEKDEL sequence in protein expression constructs. Protein Expression and Purification 2009; 66:46-51.
Pirkoohi MH and Zibaee S: Plant-based recombinant vaccines. International Journal of Agriculture and crop Sciences 2013; 6:27-30.
Imani J, Berting A, Nitsche S, Schaefer S, Gerlich W and Neumann K-H: The integration of a major hepatitis B virus gene into cell-cycle synchronized carrot cell suspension cultures and its expression in regenerated carrot plants. Plant cell, tissue and organ culture 2002; 71:157-164.
Laere E, Ling APK, Wong YP, KoH RY, Lila MAM and Hussein S: Plant Based Vaccines: Production and Challenges. Journal of Botany 2016; 2016.
Xu J, Ge X and Dolan MC: Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnology Advances 2011; 29:278-299.
Deineko EV, Zagorskaya AA, Pozdnyakov SG, Filipenko EA, Permyakova NV, Sidorchuk YV, Uvarova EA, Pozdnyakova LD, Shumny VK, Vlasov VV, Hammond RV and Shchelkunov SN: Comparative analysis of HBV M-antigen production in leaves of individual transgenic carrot plants. Doklady Biochemistry and Biophysics 2009; 425:76-79.
Guan Z-j, Guo B, Huo Y-l, Guan Z-p, Dai J-k and Wei Y-h: Recent advances and safety issues of transgenic plant-derived vaccines. Applied microbiology and biotechnology 2013; 97:2817-2840.
Miki B and Mchugh S: Selectable marker genes in transgenic plants: applications, alternatives and biosafety. Jounal of Biotechnology 2004; 107:193-232.
Zhang H, Liu M, Li Y, Zhao Y, He H, Yang G and Zheng C: Oral immunogenicity and protective efficacy in mice of a carrot-derived vaccine candidate expressing UreB subunit against Helicobacter pylori. Protein Expression and Purification 2010; 69:127-131.
Rosales-Mendoza S, Soria-Guerra RE, de Jesus Olivera-Flores MT, Lopez-Revilla R, Arguello-Astorga GR, Jimenez-Bremont JF, Garcia-de la Cruz RF, Loyola-Rodriguez JP and Alpuche-Solis AG: Expression of Escherichia coli heat-labile enterotoxin b subunit (LTB) in carrot (Daucus carota L.).Plant Cell Reports 2007; 26:969-976.
Monreal-Escalante E, Govea-Alonso DO, Hernandez M, Cervantes J, Salazar-Gonzalez JA, Romero-Maldonado A, Rosas G, Garate T, Fragoso G, Sciutto E and Rosales-Mendoza S: Towards thedevelopment of an oral vaccine against porcine cysticercosis: expression of the protective HP6/TSOL18 antigen in transgenic carrots cells. Planta 2016; 243:675685.
Weiner HL, Cunha APd, Quintana F and Wu H: Oral Tolerance. Immunological reviews 2005; 206:232-259.
Kwon KC and Daniell H: Low-cost oral delivery of protein drugs bioencapsulated in plant cells. Plant Biotechnology Journal 2015; 13:1017-1022.
Mowat AM: Anatomical basis of tolerance and immunity to intestinal antigens. Nature Reviews Immunology 2003; 3:331-341.
Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G, Förster R and Pabst O: Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. Journal of Experimental Medicine 2006; 203:519-527.
Freytag LC and Clements JD: Mucosal adjuvants. Vaccine 2005; 23:1804-1813.
Zeng L: Mucosal adjuvants: Opportunities and challenges. Human Vaccines & Immunotherapeutics 2016; 12:2456-2458.
Mishra N, Gupta PN, Khatri K and Vyas SP: Edible vaccines: A new approach to oral immunization. Indian Journal of Biotechnology 2008; 7:283-294.
Rigano MM, Guzman GD, Walmsley AM, Frusciante L and Baron A: Production of Pharmaceutical protein in solanaceae food crops. International Journal of Molecular Science 2013; 14:2753-2773.
Fu ZF, Dietzschold B, Schumacher CL, Wunner WH, Ertl HC and Koprowski H: Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proceedings of the National Academy of Sciences of the United States of America 1991; 88:20012005.
Li J, Fei L, Mou Z, Wei J, Tang Y, He H, Wang L and Wu Y: Immunogenicity of a plant-derived edible rotavirus subunit vaccine transformed over fifty generations. Virology 2006; 356:171.
Tat'kov S, Smirnova O, Tsivkovskii R, Kochneva G, Kuz'micheva G, Khristoforov V, Kosarev I, Chernykh E, Khonina N and Lebedev L: Mutant human gamma-interferon with a truncated C-terminus and its properties. Doklady biochemistry: proceedings of the Academy of Sciences of the USSR, Biochemistry section 2000; 372:112.
Aggani SL; Edible Vaccines: A new Approach for Immunization in Plant Biotechnology. Scholars Academic Journal of Pharmacy 2013; 2: 227232.
Uvarova EA, Belavin PA, Permyakova NV, Zagorskaya AA, Nosareva OV, Kakimzhanova AA and Deineko EV: Oral Immunogenicity of plantmade Mycobacterium tuberculosis ESAT6 and CFP10. BioMed Research International 2013; 2013.
Chan HT and Daniell H: Plant-made oral vaccines against human infectious diseases-Are we there yet?. Plant Biotechnology Journal 2015; 13:1056-1070.
Carter Iii JE and Langridge WHR: Plant-Based Vaccines for Protection Against Infectious and Autoimmune Diseases. Critical Reviews in Plant Sciences 2002; 21:93-109.
Streatfield SJ and Howard JA: Plant production systems for vaccines. Expert Review of Vaccines 2003; 2:763-775.
Jaskiewicz K, Louw JA and Marks IN: Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori. Digestive Diseases and Sciences 1993; 38:937-943.
Mishori R, McClaskey EL and WinklerPrins VJ: Chlamydia trachomatis infections: screening, diagnosis, and management. American Family Physician 2012; 86:1127-1132.
Hendekli CM; Current therapies in rabies. Archives of Virology 2005; 150:1047-1057.
Evans CA, Gonzalez AE, Gilman RH, Verastegui M, Garcia HH, Chavera A, Pilcher JB and Tsang VC: Immunotherapy for porcine cysticercosis: implications for prevention of human disease. Cysticercosis Working Group in Peru. The American Journal of Tropical Medicine and Hygiene 1997; 56:33-37.
Published
How to Cite
Issue
Section
Copyright (c) 2018 Nipatha Issaro, Dezhong Wang, Min Liu, Boonrat Tassaneetrithep, Chintana Phawong, Triwit Rattanarojpong, Chao Jiang
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at